Navigation Links
Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting

sion proteins. These are combinations of vascular targeting agents such as bavituximab and immune system-stimulating cytokines such as interferon and interleukin-2. Peregrine's immunocytokine fusion proteins showed robust anti-tumor efficacy in animal models of melanoma and B-cell lymphoma, without the signs of toxicity that have limited the wide use of cytokines as anti-cancer agents. In particular, the 85% reduction in tumor growth observed in the B-cell lymphoma model serves as an important validation of Peregrine's VTA immunocytokine approach, and hematological cancers such as lymphoma also represent potential new cancer indications for the company.

Data on Peregrine's VTA coaguligand and VEA anti-cancer development programs.

Researchers working with Peregrine presented data on progress in the company's VTA coaguligand development program, its VEA program and its initiatives to develop second-generation anti-PS monoclonal antibodies.

    *  Peregrine's VTA coaguligands program has developed fusion proteins that

       combine a vascular targeting antibody with modified tissue factor, a

       protein that can induce blocking and destruction of targeted blood

       vessels.  Since Peregrine's VTAs specifically target tumor blood

       vessels, the fusion proteins are intended to affect only the

       established blood vessels that are essential for the survival and

       growth of tumors.  Researchers reported on their progress in

       successfully developing and testing a series of VTA coaguligands that

       currently are in further testing in animal cancer models.


    *  Peregrine researchers gave an oral presentation on novel methods the

       company is employing in its drug discovery efforts for its VEA program.

       VEAs are a new class of therapeutics comprised of tumor-specific

       antibodies fused to vasoactive compound
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
4. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
5. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
11. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:2/27/2015)... 2015 WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), ... serving the pharmaceutical, biotechnology, and medical device industries with ... the United States , congratulates our partner ... U.S. FDA for ibalizumab (TMB355). The FDA designates a ... alone or in combination with one or more other ...
(Date:2/27/2015)... , Feb. 27, 2015  Acsis Inc., the ... serialization solutions, announced today that John DiPalo , ... Supply & Demand Chain Executive 2015 Provider ... who are leading initiatives to help prepare their companies, ... today,s business climate. This year,s list of Provider Pros ...
(Date:2/27/2015)... , Feb. 27, 2015 Securities lawyers ... board of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP ... per share. Concerned SLXP investors are encouraged to contact ... The investigation focuses upon the shareholder value ... Salix shareholders would receive only $158.00 per share in ...
Breaking Medicine Technology:WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2
... Calif., Nov. 15, 2010 diaDexus, Inc. (OTC Bulletin Board: ... development and commercialization of patent-protected in vitro diagnostic ... results for the third quarter of 2010. Total revenues for ... growth over total revenues of $2.5 million for the third ...
... SPRING, Md., Nov. 15, 2010 The U.S. ... aimed at facilitating the development of safer, more ... rhythms through improved design and manufacturing practices. ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) External ...
Cached Medicine Technology:diaDexus, Inc. Reports 2010 Third Quarter Financial Results 2diaDexus, Inc. Reports 2010 Third Quarter Financial Results 3diaDexus, Inc. Reports 2010 Third Quarter Financial Results 4diaDexus, Inc. Reports 2010 Third Quarter Financial Results 5FDA Launches Initiative to Develop Innovative External Defibrillators 2FDA Launches Initiative to Develop Innovative External Defibrillators 3
(Date:2/28/2015)... AB (PRWEB) February 28, 2015 The ... is now a distributor of the machine. The Heart ... of their license, like a franchise model. The goal ... prevent and reverse heart disease. To buy External ... Fit Clinic can help individuals through this process and ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax ... business consulting services in addition to a variety of ... succession planning. Company finances are a complicated matter that ... of this, complex Canadian tax laws can make it ... result, Mew and Company works to advise their clients ...
(Date:2/28/2015)... A study out of the University ... procedure for the treatment of a hereditary ocular condition ... Authored by Dr. Robert MacLaren, professor of ophthalmology at ... Medical Journal on January 16, 2014 , the study ... disorder that mostly affects men and leads to the ...
(Date:2/28/2015)... 28, 2015 Pioneer Millworks reclaimed USA ... Architecture & Construction Materials Show, an annual, premier sustainable ... 1,000 suppliers and top manufacturers of the latest building ... products sourced and manufactured by Pioneer Millworks from ... in Japan at restaurants, hotels, retailers, and corporate offices. ...
(Date:2/28/2015)... India Network Foundation, a ... insurance programs for visitors coming to the United States ... traveling to the United States are suffering from one ... pressure. These diseases are so common among the elderly ... medical conditions. There were 66.8 million cases of diabetes ...
Breaking Medicine News(10 mins):Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3
... For the second year in a row Inc.,recognized ... 5000,Fastest-Growing Private Companies in America. The Inc. 5000, an ... that are too,big to grow at the pace required ... a whole, these companies represent the entrepreneurial engine,driving the ...
... Sept. 8 Conseco, Inc. (NYSE:,CNO) will host ... on Thursday, September 18, 2008 at 10:00 a.m. ... issued the supplement to provide a more,detailed description ... 30,2008., A copy of this supplement can ...
... And medications do little to influence the link, study finds ... or less of sleep a night increases the risk of ... study. , It also found that the use of sleep ... sleep and fall risk. , Researchers measured sleep, sleep efficiency ...
... results from its first comprehensive study which focused on ... reported in the Sept. 4, 2008, advance edition of ... more than 100 investigators from seven cancer centers and ... tumor samples from 91 glioblastoma multiforme (GBM) patients. , ...
... Spherix Incorporated,(Nasdaq: SPEX ) announced that it will ... a Special Meeting of Stockholders on,November 17, 2008, in ... price,requirements for continued listing on the NASDAQ Global Market. ... notice of, and,to vote at, the Special Meeting is ...
... cheating during the course of a relationship varies between 40 ... student at the Universit de Montral,s Department of Psychology. ... with the best of intentions things don,t always turn out ... why people are willing to conduct themselves in ways that ...
Cached Medicine News:Health News:Vickie Milazzo Institute Makes Inc.'s List of Top 5000 Fastest-Growing Private Companies in America 2Health News:Conseco Announces Call on Investment Portfolio Supplement 2Health News:Fall Risk Higher in Older Women Who Sleep Less 2Health News:The Cancer Genome Atlas reports first results, Johns Hopkins Kimmel Cancer Center collaborates 2Health News:Spherix Incorporated to Seek Stockholder Approval of Reverse Stock Split 2Health News:Infidelity dissected: New research on why people cheat 2
Curved Shaft with 5mm Platform; 1x2, 0.12 mm teeth; In Titanium....
0.5mm 1X2 Teeth with 6mm Tying Platform; in Stainless Steel 125...
... 226 trial lenses with polished metal rims ... Concave Lenses: 0.12 to 20.00 Diopters (0.25D ... to 20.00 Diopters (0.25D increments), ,34 Cylindrical ... increments), ,34 Cylindrical Convex Lenses: 0.12 to ...
... Master is designed and constructed ... service and give the professional ... procedures. It embodies the characteristics ... most, including accuracy, speed, ease, ...
Medicine Products: